Open AccessValidation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease
Author(s) -
Gregorio Juan Martínez-Romero,
A. Alvariño,
Esther Hinojosa,
M Mora,
L. Oltra,
Nuria Maroto,
Isabel Ferrer,
María Dolores Hinojosa,
Joaquín Hinojosa
Publication year - 2019
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2019.5600/2018
Subject(s) - medicine , adalimumab , therapeutic drug monitoring , inflammatory bowel disease , rheumatoid arthritis , cohort , population , pharmacokinetics , disease , gastroenterology , environmental health
therapeutic monitoring of anti-TNF drugs and anti-drug antibody levels are useful for clinical decision-making, via the rationalization and optimization of the use of anti-TNF treatments. The objective of the present study was to validate the model of Ternant et al., in a cohort of patients with inflammatory bowel diseases (IBD). This model was originally established for patients with rheumatoid arthritis and was used in this study to optimize the adalimumab (ADA) dose and predict ADA trough levels (ATL).